| Literature DB >> 26078913 |
J J Vargas-Duarte1, H Lozano-Márquez2, H A Grajales-Lombana3, C Manrique-Perdomo3, D A Martínez-Bello4, C Saegerman5, M Raes6, N Kirschvink6.
Abstract
This study tested the impact of moxidectin at peripartum on nematode fecal egg count (FEC) and clinical parameters on ewes in the high altitude tropical Andes of Colombia. FEC and clinical evaluations were performed on 9 occasions in 43 naturally infected ewes before and during gestation and after lambing. Moxidectin (Mox, 200 µg kg(-1)) was applied at late pregnancy (T 1, n = 15) or 48 hours after parturition (T 2, n = 14). 14 untreated ewes served as controls (C). Suckling lambs (n = 58) remained untreated and underwent four clinical and parasitological evaluations until 8 weeks after birth. Mox efficacy equaled 99.3% (T 1) and 96.9% (T 2). Highest mean FEC value reflecting periparturient nematode egg rise (PPER) was recorded in C ewes at 4-6 weeks after lambing. Significant FEC reductions were found in T 1 (94.8%) and T 2 (96.7%) ewes (p < 0.05). All lambs showed a significant and ewes-group independent increase in FEC before weaning (p < 0.05). Clinical parameters (anemia and diarrhea) showed time- and treatment-related differences (p < 0.05). Monitoring of FEC and clinical parameters linked to gastrointestinal parasite infections allowed demonstrating that postpartum or preweaning are two critical periods to nematode infection for sheep raised under tropical Andes high altitude conditions. Use of Mox as anthelmintic treatment prevented PPER.Entities:
Year: 2015 PMID: 26078913 PMCID: PMC4442306 DOI: 10.1155/2015/932080
Source DB: PubMed Journal: Vet Med Int ISSN: 2042-0048
Figure 1Experimental design to describe periparturient nematode egg rise (PPER) of ewes naturally infected with gastrointestinal nematodes and to measure the efficacy and persistency of peripartum strategic treatment with moxidectin (Mox) either at the onset of late pregnancy (TT1) or at the end of immediate peripartum (TT2) period under tropical Andes high altitude conditions. Parasitological and clinical evaluations included FEC by McMaster test, anemia detection by FAMACHA© system, diarrhea assessment by Dag scoring, body weight, and body condition assessment. Fecal egg count reduction (FECR) was employed to test posttreatment moxidectin efficacy 15 days after treatment (PEMox and PEMox), the prevention of PPER at late postpartum (PPERPre) period, and preweaning persistency (PW). Ewes in control group (C) and offspring of all ewes were untreated against gastrointestinal nematodes. D: dry ewes; M: mating; MP: midpregnancy; LP: late pregnancy; Ipr: immediate postpartum; Epp: early postpartum; Ipp: intermediate postpartum; LPp: late postpartum; and PW: preweaning.
Figure 2Mean gastrointestinal parasite burdens (± standard error of mean) registered during one complete reproductive cycle in ewes and their offspring. (a) shows the peak in FEC at late pregnancy in C ewes (PPER) and the significant (b) and sustained FECR induced by T 1 and T 2 peripartum strategic treatment with moxidectin (two-factor ANOVA, p < 0.05) preventing the PPER (PPERPre). (b) shows the significant increase in FEC at preweaning (b) in ewes' offspring (two-factor ANOVA, p < 0.05). Adult ewes n = 43 (14 C, 15 T 1, and 14 T 2). Suckling lambs n = 58 lambs (18 born from C ewes, 20 from T 1 ewes, and 20 from T 2 ewes).
Treatment-induced differences in the median of ratio change of clinical (FAMACHA© and Dag score) and zootechnical (body weight and body condition) parameters.
| Measured parameters | Median (min–max) | ||
|---|---|---|---|
| Untreated control group | Late pregnancy Mox injection | 48 hours postlambing Mox injection | |
| Change ratio | |||
| FAMACHA∗∗ | 0.73 (0.5–1)a | 1 (0.67–1.25)b | 0.67 (0.67–1)a |
| Dag score∗∗ | 1.75 (0.5–2)a | 1 (0.67–3)b | 1.16 (0.67–2)ab |
| Body weight | 1.19 (1.06–1.28) | 1.16 (1.02–1.4) | 1.19 (1.05–1.42) |
| Body condition | 1.04 (0.82–1.03) | 1 (0.7–1.2) | 1 (0.67–1.3) |
Data were calculated by dividing the median of the parameter values before treatment (dry, mating, midpregnancy, and late pregnancy) over its median after treatment (early, intermediate, late, and preweaning period). Min: minimum value; max: maximum value; FAMACHA© values (1–5); Dag score values (0–5); body condition values (1–5). ∗Three C ewes with high FEC and associated clinical signs were excluded after intermediate postpartum period due to Mox treatment. ∗∗Significant differences between treatments (one-way ANOVA, p > 0.05). Treatment differences (Tukey test, p > 0.05) are denoted by superscripts.
FECR induced by moxidectin strategic treatment of periparturient ewes during the same reproductive cycle.
| Time of treatment | Evaluated period | Mean FEC ± SEM | Efficacy of treatment | ||
|---|---|---|---|---|---|
| Untreated | Treated ewes | % FECR | 95% CI | ||
| Before lambing ( | Before treatment | 1705 ± 537 | 1060 ± 314 | — | — |
| 15 days after treatment (PEMox)∗∗ | 745 ± 351 | 3 ± 3 | 99.3 | 97–100 | |
| Late postpartum (PPERPre)∗∗ | 4168 ± 1417 | 217 ± 172 | 94.8 | 66.2–99.6 | |
| Preweaning (PWPer)∗∗ | 2582 ± 1205 | 123 ± 59 | 95.2 | 79.4–98.9 | |
|
| |||||
| 48 h after lambing ( | Before treatment | 1277 ± 491 | 1043 ± 358 | — | — |
| 15 days after treatment (PEMox)∗∗ | 1205 ± 316 | 27 ± 18 | 96.1 | 89.1–100 | |
| Late postpartum (PPRPre)∗∗ | 4168 ± 1417 | 136 ± 64 | 96.7 | 85.9–99.5 | |
| Preweaning (PWPer)∗∗ | 2582 ± 1205 | 193 ± 140 | 92.5 | 53–98.8 | |
T 1: late pregnancy treated group; T 2: 48 hours postlambing treated group; PEMox: posttreatment efficacy induced by moxidectin; PPERPre: PPER prevention induced by moxidectin; PWPer: preweaning moxidectin persistency; FEC: fecal egg count; SEM: standard error of mean; FECR: fecal egg count reduction; 95% CI: 95% confidence intervals. Three C ewes with high FEC and associated clinical signs were excluded after intermediate postpartum period due to Mox treatment by ethical considerations and their data were not included in the analysis. Significant effect of treatments (one-way ANOVA and Tukey tests, p < 0.05) in FEC by evaluated period.